Harvard research findings: The weight loss drug Ozempic is associated with rare vision loss

On July 3rd, Jin10.com reported that the analysis of doctors from Massachusetts Eye and Ear, a hospital affiliated with Harvard University, showed that Novo Nordisk's popular weight-loss drugs Ozempic and Wegovy appear to be associated with an increased risk of rare vision loss. Research on medical records showed that compared to those who used other brand-name weight-loss drugs, patients who used Novo Nordisk's weight-loss drugs to lose weight were seven times more likely to develop non-arteritic anterior ischemic optic neuropathy (NAION).

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)